导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.81% | 1747/4773 |
| 近一周 | -0.04% | 879/5465 |
| 近一月 | 5.27% | 49/5421 |
| 近一季 | 6.37% | 259/5231 |
| 近半年 | 6.05% | 766/4920 |
| 近一年 | 5.07% | 1769/4394 |
| 近两年 | 43.03% | 1770/2954 |
| 近三年 | 53.15% | 518/2253 |
| 成立以来 | 69.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.73% 2884/4961 |
-8.12% 3838/5312 |
- - |
- - |
| 2025 | 11.71% 2731/4813 |
2.73% 1280/3635 |
12.33% 103/4076 |
-8.76% 4059/4524 |
6.10% 379/4813 |
| 2024 | 41.57% 11/3463 |
10.56% 52/2808 |
7.24% 93/3014 |
13.11% 2241/3129 |
5.56% 591/3463 |
| 2023 | -1.30% 501/2656 |
-2.33% 1962/2280 |
2.49% 137/2385 |
5.38% 89/2515 |
-6.44% 1776/2655 |
| 2022 | -4.04% 78/2207 |
2.35% 56/1919 |
-1.29% 1700/2016 |
-8.29% 187/2113 |
3.57% 671/2208 |
| 2021 | 4.19% 589/1822 |
11.21% 27/1255 |
-0.06% 1124/1330 |
-5.96% 883/1466 |
-0.31% 1220/1822 |
| 2020 | 9.15% 846/1250 |
-12.44% 885/1028 |
4.18% 915/1067 |
7.69% 765/1164 |
11.11% 564/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华夏中证银行ETF VS. 长安沪深300非周期A(740101) |